{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:17:34Z","timestamp":1782184654145,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To demonstrate the feasibility of continuous infusion of meropenem\u2013vaborbactam to optimize the treatment of carbapenem-resistant Enterobacterales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Report of a case of a <jats:italic>Klebsiella pneumoniae<\/jats:italic> carbapenemase (KPC)-producing <jats:italic>K. pneumoniae<\/jats:italic> bloodstream infection comfirmed by whole genome sequencing and therapeutic drug monitoring (TDM) of meropenem.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A patient with augmented renal clearance (ARC) went into septic shock caused by an ST11 KPC-3-producing <jats:italic>K.\u00a0pneumoniae<\/jats:italic> bloodstream infection that was successfully treated with a continuous infusion of meropenem\u2013vaborbactam at a dosage of 1\u00a0g\/1\u00a0g q4h as a 4-h infusion. TDM confirmed sustained concentrations of meropenem ranging from 8 to 16\u00a0mg\/L throughout the dosing interval.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Continuous infusion of meropenem\u2013vaborbactam was feasible. It could be appropriate for optimizing the management of critically ill patients with ARC, as it resulted in antibiotic concentrations above the minimum inhibitory concentration for susceptible carbapenem-resistant Enterobacterales (up to 8\u00a0mg\/L) throughout the dosing interval.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-023-02055-2","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T03:24:19Z","timestamp":1686021859000},"page":"1835-1840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Continuous infusion of meropenem\u2013vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-0901","authenticated-orcid":false,"given":"Romaric","family":"Larcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Laffont-Lozes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayma","family":"Naciri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9a","family":"Gandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Magnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Sotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"2055_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet Lond Engl. 2022;399:629\u201355.","journal-title":"Lancet Lond Engl"},{"key":"2055_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40121-020-00344-z","volume":"9","author":"E Wenzler","year":"2020","unstructured":"Wenzler E, Scoble PJ. An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem\u2013vaborbactam. Infect Dis Ther. 2020;9:769.","journal-title":"Infect Dis Ther"},{"key":"2055_CR3","unstructured":"Summary of product characteristics: Vaborem [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaborem-epar-product-information_en.pdf. Accessed 23 Mar 2023"},{"key":"2055_CR4","doi-asserted-by":"publisher","first-page":"106569","DOI":"10.1016\/j.ijantimicag.2022.106569","volume":"59","author":"CM Silva","year":"2022","unstructured":"Silva CM, Baptista JP, Santos I, Martins P. Recommended antibiotic dosage regimens in critically ill patients with augmented renal clearance: a systematic review. Int J Antimicrob Agents. 2022;59:106569.","journal-title":"Int J Antimicrob Agents"},{"key":"2055_CR5","doi-asserted-by":"publisher","first-page":"e02647","DOI":"10.1128\/spectrum.02647-22","volume":"11","author":"N Rebold","year":"2023","unstructured":"Rebold N, Lagnf AM, Alosaimy S, Holger DJ, Witucki P, Mannino A, et al. Risk factors for carbapenem-resistant enterobacterales clinical treatment failure. Goldberg JB, editor. Microbiol Spectr. 2023;11:e02647-22.","journal-title":"Microbiol Spectr"},{"key":"2055_CR6","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1128\/AAC.00176-16","volume":"60","author":"T Legrand","year":"2016","unstructured":"Legrand T, Vodovar D, Tournier N, Khoudour N, Hulin A. Simultaneous determination of eight \u03b2-lactam antibiotics, amoxicillin, cefazolin, cefepime, cefotaxime, ceftazidime, cloxacillin, oxacillin, and piperacillin, in human plasma by using ultra-high-performance liquid chromatography with ultraviolet detection. Antimicrob Agents Chemother. 2016;60:4734\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"2055_CR7","volume":"7","author":"C Jamin","year":"2021","unstructured":"Jamin C, De Koster S, van Koeveringe S, De Coninck D, Mensaert K, De Bruyne K, et al. Harmonization of whole-genome sequencing for outbreak surveillance of enterobacteriaceae and enterococci. Microb Genom. 2021;7: 000567.","journal-title":"Microb Genom"},{"key":"2055_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz M-H, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent \u03b2-Lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194:681\u201391.","journal-title":"Am J Respir Crit Care Med"},{"key":"2055_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"2055_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"The Infection Section of European Society of Intensive Care Medicine (ESICM), Pharmacokinetic\/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC), Abdul-Aziz MH, Alffenaar J-WC, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127.","journal-title":"Intensive Care Med"},{"key":"2055_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/IDR.S199639","volume":"12","author":"R Ranjbar","year":"2019","unstructured":"Ranjbar R, Kelishadrokhi AF, Chehelgerdi M. Molecular characterization, serotypes and phenotypic and genotypic evaluation of antibiotic resistance of the Klebsiella pneumoniae strains isolated from different types of hospital-acquired infections. Infect Drug Resist. 2019;12:603\u201311.","journal-title":"Infect Drug Resist"},{"key":"2055_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01000","author":"C Rodrigues","year":"2016","unstructured":"Rodrigues C, Bavlovi\u010d J, Machado E, Amorim J, Peixe L, Novais \u00c2. KPC-3-producing Klebsiella pneumoniae in Portugal linked to previously circulating non-CG258 lineages and uncommon genetic platforms (Tn4401d-IncFIA and Tn4401d-IncN). Front Microbiol. 2016. https:\/\/doi.org\/10.3389\/fmicb.2016.01000.","journal-title":"Front Microbiol"},{"key":"2055_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/antibiotics9110806","volume":"9","author":"AM Guerra","year":"2020","unstructured":"Guerra AM, Lira A, Lameir\u00e3o A, Selaru A, Abreu G, Lopes P, et al. Multiplicity of carbapenemase-producers three years after a KPC-3-producing K. pneumoniae ST147-K64 hospital outbreak. Antibiotics. 2020;9:806.","journal-title":"Antibiotics"},{"key":"2055_CR14","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1128\/aac.00447-22","volume":"66","author":"CA Hobson","year":"2022","unstructured":"Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, et al. Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview. Antimicrob Agents Chemother. 2022;66:e00447-e522.","journal-title":"Antimicrob Agents Chemother"},{"key":"2055_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/jac\/dkq044","volume":"65","author":"K Berthoin","year":"2010","unstructured":"Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65:1073\u20135.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02055-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:05:55Z","timestamp":1700651155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02055-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2055"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02055-2","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RL has received consulting fees from MSD, payment or honoraria for lectures, presentations, speakers\u2019 bureaus or educational events from BioM\u00e9rieux, MSD, Pfizer and Shionogi, and support for attending meetings and\/or travel from BioM\u00e9rieux, MSD, Pfizer and Shionogi. AS has received consulting fees from Besins Healthcare and Karo Pharma, support for attending meetings and\/or travel from Pfizer and MSD, and participates free of charge on advisory boards of Biofilm Control and CTX Laboratory. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required by the local ethics committee for the case report. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient provided written informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patient provided written informed consent for the publication of this report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}